Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
Not Confirmed
Not Confirmed
07-09 April, 2026
Health 2.0 ConferenceHealth 2.0 Conference
Not Confirmed
Not Confirmed
07-09 April, 2026
Not Confirmed
Not Confirmed
09-12 April, 2026
List your booth number for exhibitions, ask us
CONTACT DETAILS






Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
07-09 April, 2026
Health 2.0 ConferenceHealth 2.0 Conference
Industry Trade Show
Not Confirmed
07-09 April, 2026
Industry Trade Show
Not Confirmed
09-12 April, 2026
Digital content

12 Dec 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/astellas-and-mbc-biolabs-announce-2023-future-innovator-prize-awarded-to-tippingpoint-biosciences-and-altay-therapeutics-302013297.html
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The investment will support Altay Therapeutics’ unique approach to finding an inhibitor of DUX4, a key transcription factor implicated in FSHD, that could provide an effective disease-modifying treatment.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: DiscoveryProduct Type: Undisclosed
Sponsor: SOLVE FSHD
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Financing September 21, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Discovery
Partner/Sponsor/Collaborator : SOLVE FSHD
Deal Size : $3.0 million
Deal Type : Financing
SOLVE FSHD Invests US$3 Million in Altay Therapeutics
Details : The investment will support Altay Therapeutics’ unique approach to finding an inhibitor of DUX4, a key transcription factor implicated in FSHD, that could provide an effective disease-modifying treatment.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 21, 2022

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE